For the Inventor, By the Inventor

Enter assignee name

Monmouth Junction, NJ, United States of America

Tris Pharma, Inc.

USPTO Granted Patents = 58

% Expired Patents = 5.2

CIPO Patents = 2

EPO Patents = 6

Trademarks = 11

Forward Citations = 2,276

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Yu-Hsing Tu (44 out of 53 patents)

Ketan Mehta (32 out of 32 patents)

Ashok Perumal (18 out of 27 patents)

4. Kalyan Kathala (16 out of 28 patents)

5. Paras Rameshlal Jain (7 out of 7 patents)

6. Sachin Vasant Chaudhari (7 out of 7 patents)

7. Andrea Nelson (6 out of 6 patents)

8. Quin-Zene Chen (5 out of 5 patents)

9. Harsh Mehta (5 out of 5 patents)

10. Mahendra Shah (2 out of 2 patents)

11. Grishma Patel (2 out of 2 patents)

12. Alivia Chaudhuri (1 out of 1 patent)

13. Nemichand B Jain (1 out of 17 patents)

14. Shivanand Puthli (1 out of 1 patent)

15. Mahesh Chavan Patil (1 out of 1 patent)

Core Competencies:

Extended Release Tablets

Methylphenidate

Clonidine

GHB Compositions

Benzonatate

Drug-Ion Exchange Resins

Gastro-Retentive Systems

Floating Polymer Networks

Abuse Resistant Opioids

Powder Compositions

Trigger Pulse Release

Solid Tablets

58 patents: Sort by Forward Citations

1. 12734132 - Extended release amphetamine tablets (2026-09-15),

2. 12605333 - Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release (2026-04-21),

3. 12576032 - Liquid clonidine extended release composition (2026-03-17),

4. 12533314 - Low sodium oxybate once nightly composition (2026-01-27),

5. 12514818 - Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system (2026-01-06),

6. 12458592 - Extended release amphetamine tablets (2025-11-04),

7. 12201720 - Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release (2025-01-21),

8. 12076441 - Extended release amphetamine tablets (2024-09-03),

9. 11938224 - Benzonatate modified release solid tablets and capsules (2024-03-26),

10. 11918689 - Liquid clonidine extended release composition (2024-03-05),

11. 11890267 - Benzonatate modified release solid tablets and capsules (2024-02-06),

12. 11666546 - GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system (2023-06-06),

13. 11633389 - Methylphenidate extended release chewable tablet (2023-04-25),

14. 11590228 - Extended release amphetamine compositions (2023-02-28),

15. 11590081 - Extended release amphetamine tablets (2023-02-28),

Tris Pharma, Inc., based in Monmouth Junction, NJ, specializes in the development and manufacturing of modified release formulations. The company focuses on innovative drug delivery systems, particularly in the areas of extended release tablets and gastro-retentive systems. Their expertise encompasses a range of therapeutic compounds, including methylphenidate, clonidine, and benzonatate, utilizing advanced technologies such as drug-ion exchange resins and floating polymer networks to enhance medication efficacy and patient compliance.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

58 Patents

#2 in Monmouth Junction, NJ

#257 in New Jersey

#6,151 in US

#12,380 in the World

Monmouth Junction, NJ, United States of America

Tris Pharma, Inc.

Forward Citations = 2,276

19 inventors:

Yu-Hsing Tu (44 out of 53 patents)

Ketan Mehta (32 out of 32 patents)

Ashok Perumal (18 out of 27 patents)

4. Kalyan Kathala (16 out of 28 patents)

5. Paras Rameshlal Jain (7 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…